Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921034 | 0.86 | ALDH1A1 (0.33) | MEN1KMT2AKDM4EALDH1A1ATM | |
| SCHEMBL11921035 | 0.74 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL11921031 | 0.71 | ALDH1A1 (0.38) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL13875989 | 0.71 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL26164078 | 0.71 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL26164080 | 0.71 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL11921036 | 0.68 | ALDH1A1 (0.40) | KDM4EALDH1A1LMNANPSR1ATM | |
| SCHEMBL21074258 | 0.65 | ALDH1A1 (0.39) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL19999692 | 0.65 | ALDH1A1 (0.39) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL9891022 | 0.65 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144869-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | UDC IRELAND LIMITED (IE) | 2022-05-12 | — | — | US | disclosed |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | UDC IRELAND LIMITED (IE) | 2021-11-30 | — | — | US | disclosed |
| US-20200373503-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2011051404-A1 | HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885KMT2A 2077/4885KDM4E 3813/4885 |
| US-20220144869-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3710/4885KMT2A 2306/4885KDM4E 4143/4885 |
| US-20200373503-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885KMT2A 2077/4885KDM4E 3813/4885 |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885KMT2A 2077/4885KDM4E 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.